238 related articles for article (PubMed ID: 29275373)
1. Randomized Trial of the Effects of Insulin and Metformin on Myocardial Injury and Stress in Diabetes Mellitus: A Post Hoc Exploratory Analysis.
Srivastava PK; Pradhan AD; Cook NR; Ridker PM; Everett BM
J Am Heart Assoc; 2017 Dec; 6(12):. PubMed ID: 29275373
[TBL] [Abstract][Full Text] [Related]
2. Impact of Modifiable Risk Factors on B-type Natriuretic Peptide and Cardiac Troponin T Concentrations.
Srivastava PK; Pradhan AD; Cook NR; Ridker PM; Everett BM
Am J Cardiol; 2016 Feb; 117(3):376-81. PubMed ID: 26739393
[TBL] [Abstract][Full Text] [Related]
3. Effect of IL-6 receptor blockade on high-sensitivity troponin T and NT-proBNP in rheumatoid arthritis.
Welsh P; Tuckwell K; McInnes IB; Sattar N
Atherosclerosis; 2016 Nov; 254():167-171. PubMed ID: 27744141
[TBL] [Abstract][Full Text] [Related]
4. High-sensitivity troponin T improves the prognostic value of N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: results from the LURIC Study.
Ivandic BT; Spanuth E; Kleber M; Grammer TB; März W
Clin Chem Lab Med; 2011 Jun; 49(6):1053-8. PubMed ID: 21574877
[TBL] [Abstract][Full Text] [Related]
5. Metformin and N-terminal pro B-type natriuretic peptide in type 2 diabetes patients, a post-hoc analysis of a randomized controlled trial.
Top WMC; Lehert P; Schalkwijk CG; Stehouwer CDA; Kooy A
PLoS One; 2021; 16(4):e0247939. PubMed ID: 33830998
[TBL] [Abstract][Full Text] [Related]
6. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial.
Pradhan AD; Everett BM; Cook NR; Rifai N; Ridker PM
JAMA; 2009 Sep; 302(11):1186-94. PubMed ID: 19755697
[TBL] [Abstract][Full Text] [Related]
7. Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes.
Januzzi JL; Butler J; Jarolim P; Sattar N; Vijapurkar U; Desai M; Davies MJ
J Am Coll Cardiol; 2017 Aug; 70(6):704-712. PubMed ID: 28619659
[TBL] [Abstract][Full Text] [Related]
8. Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.
Tanaka A; Toyoda S; Imai T; Shiina K; Tomiyama H; Matsuzawa Y; Okumura T; Kanzaki Y; Onishi K; Kiyosue A; Nishino M; Sakata Y; Node K;
Cardiovasc Diabetol; 2021 Sep; 20(1):175. PubMed ID: 34479543
[TBL] [Abstract][Full Text] [Related]
9. Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.
Zelniker TA; Wiviott SD; Mosenzon O; Goodrich EL; Jarolim P; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding J; Averkov O; Budaj A; Parkhomenko A; Ray KK; Gause-Nilsson I; Langkilde AM; Fredriksson M; Raz I; Sabatine MS; Morrow DA
JAMA Cardiol; 2023 May; 8(5):503-509. PubMed ID: 36857035
[TBL] [Abstract][Full Text] [Related]
10. N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk.
Idzerda NMA; Persson F; Pena MJ; Brenner BM; Brunel P; Chaturvedi N; McMurray JJ; Parving HH; de Zeeuw D; Heerspink HJL
Diabetes Obes Metab; 2018 Dec; 20(12):2899-2904. PubMed ID: 29987919
[TBL] [Abstract][Full Text] [Related]
11. Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58.
Zelniker TA; Morrow DA; Mosenzon O; Goodrich EL; Jarolim P; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding J; Bode C; Lewis BS; Gause-Nilsson I; Langkilde AM; Fredriksson M; Raz I; Sabatine MS; Wiviott SD
Eur J Heart Fail; 2021 Jun; 23(6):1026-1036. PubMed ID: 33269486
[TBL] [Abstract][Full Text] [Related]
12. High-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide (NT-proBNP) and risk of incident heart failure in patients with CKD: the Chronic Renal Insufficiency Cohort (CRIC) Study.
Bansal N; Hyre Anderson A; Yang W; Christenson RH; deFilippi CR; Deo R; Dries DL; Go AS; He J; Kusek JW; Lash JP; Raj D; Rosas S; Wolf M; Zhang X; Shlipak MG; Feldman HI
J Am Soc Nephrol; 2015 Apr; 26(4):946-56. PubMed ID: 25278510
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein CIII and N-terminal prohormone b-type natriuretic peptide as independent predictors for cardiovascular disease in type 2 diabetes.
Colombo M; Looker HC; Farran B; Agakov F; Brosnan MJ; Welsh P; Sattar N; Livingstone S; Durrington PN; Betteridge DJ; McKeigue PM; Colhoun HM
Atherosclerosis; 2018 Jul; 274():182-190. PubMed ID: 29793175
[TBL] [Abstract][Full Text] [Related]
14. Do cardiac biomarkers NT-proBNP and hsTnT predict microvascular events in patients with type 2 diabetes? Results from the ADVANCE trial.
Welsh P; Woodward M; Hillis GS; Li Q; Marre M; Williams B; Poulter N; Ryan L; Harrap S; Patel A; Chalmers J; Sattar N
Diabetes Care; 2014 Aug; 37(8):2202-10. PubMed ID: 24879844
[TBL] [Abstract][Full Text] [Related]
15. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
16. Blood pressure and cardiovascular outcomes in patients with diabetes and high cardiovascular risk.
Bergmark BA; Scirica BM; Steg PG; Fanola CL; Gurmu Y; Mosenzon O; Cahn A; Raz I; Bhatt DL;
Eur Heart J; 2018 Jun; 39(24):2255-2262. PubMed ID: 29394350
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.
Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M
Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327
[TBL] [Abstract][Full Text] [Related]
18. Role of B-Type Natriuretic Peptide and N-Terminal Prohormone BNP as Predictors of Cardiovascular Morbidity and Mortality in Patients With a Recent Coronary Event and Type 2 Diabetes Mellitus.
Wolsk E; Claggett B; Pfeffer MA; Diaz R; Dickstein K; Gerstein HC; Lawson FC; Lewis EF; Maggioni AP; McMurray JJV; Probstfield JL; Riddle MC; Solomon SD; Tardif JC; Køber L
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28554908
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of troponin T and N-terminal pro B-type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes.
Rørth R; Jhund PS; Kristensen SL; Desai AS; Køber L; Rouleau JL; Solomon SD; Swedberg K; Zile MR; Packer M; McMurray JJV
Eur J Heart Fail; 2019 Jan; 21(1):40-49. PubMed ID: 30537261
[TBL] [Abstract][Full Text] [Related]
20. NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus.
Malachias MVB; Jhund PS; Claggett BL; Wijkman MO; Bentley-Lewis R; Chaturvedi N; Desai AS; Haffner SM; Parving HH; Prescott MF; Solomon SD; De Zeeuw D; McMurray JJV; Pfeffer MA
J Am Heart Assoc; 2020 Oct; 9(19):e017462. PubMed ID: 32964800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
